<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113669">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623466</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-CL21</org_study_id>
    <nct_id>NCT01623466</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches</brief_title>
  <acronym>ATI-CL21</acronym>
  <official_title>A Randomized, Open-Label, Parallel Group Study To Evaluate Pharmacokinetic Profile, Wearability And Safety of Two Progestin-Only Patches Containing Different Doses Of Levonorgestrel (LNG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics, safety and wearability in two size patches of AG890 over eight weeks will
      be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levonorgestrel Pharmacokinetic Profile</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks post patch</time_frame>
    <description>Weekly AUCs and steady state concentration levels, Css (Study Weeks 1, 2, and 8), maximum and minimum concentration levels (Cmax and Cmin) and time to achieve them</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluations</measure>
    <time_frame>Baseline to 30 days after last patch</time_frame>
    <description>Discontinuations due to AEs, changes from screening to last assessment (post-study)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AG890-6.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate levonorgestrel delivery in AG890-6.5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG890-12.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate levonorgestrel delivery in AG890-12.5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel</intervention_name>
    <description>transdermal contraceptive delivery system</description>
    <arm_group_label>AG890-6.5</arm_group_label>
    <arm_group_label>AG890-12.5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) greater than or equal to 18.

          -  Willing to use a non-hormonal method of contraception if of childbearing potential,
             or have already undergone previous bilateral tubal ligation or hysterectomy

          -  Willing to refrain from excessive use of alcohol from 48 hours prior to patch
             application through completion of the study.

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Lactating women

          -  Status post-partum or post-abortion within a period of 2 months prior to the start of
             study medication

          -  A cervical cytology smear of Papanicolaou (Pap) class III or greater or a Bethesda
             System report of low grade squamous intraepithelial lesions (SIL) or greater

          -  Smoking

          -  Hypertension (blood pressure &gt;140 mm Hg systolic and/or &gt;90 mm Hg diastolic)

          -  Valvular heart disease with complications

          -  ECG (in women with BMI â‰¥35 kg/m2) with clinically significant findings

          -  Diabetes Mellitus

          -  History of headaches with focal neurological symptoms

          -  Uncontrolled thyroid disorder

          -  Sickle cell anemia

          -  Current or history of clinically significant depression in the last year

          -  Known disturbance of lipid metabolism

          -  Acute or chronic hepatocellular disease with abnormal liver function

          -  Hepatic adenoma or carcinoma

          -  Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use

          -  Plans for major surgery

          -  History of or existing venous and arterial thrombotic and thromboembolic disorder,
             vascular disease, cerebral vascular, or coronary artery disease

          -  Undiagnosed abnormal genital bleeding

          -  Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent
             neoplasia

          -  History or presence of dermal hypersensitivity in response to topical applications
             (bandages, surgical tape, etc.)

          -  Use of an injectable hormonal contraceptive within the past 10 months prior to the
             screening visit

          -  Use of a contraceptive implant or hormone-medicated intrauterine device (IUD) within
             1 month prior to the screening visit

          -  Use of oral contraceptives or other sex steroid hormones within 2 months prior to the
             screening visit

          -  Chronic use of any medication that might interfere with the efficacy of hormone
             contraceptives (including barbiturates, bosentan, carbamazepine, felbamate,
             griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate, and
             HIV protease inhibitors), OR use of these medications within the past 3 months prior
             to screening visit

          -  A recent history (within prior 2 years ) of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Oberstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami, FL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Foegh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Agile Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 10, 2012</lastchanged_date>
  <firstreceived_date>June 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK and Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
